Healthcare

• Five ASX-listed companies — Orthocell (ASX:OCC), Vitrafy Life Sciences (ASX:VFY), Tetratherix (ASX:TTX), AVITA Medical (ASX:AVH) and Alterity Therapeutics (ASX:ATH) — illustrate the breadth of medical innovation on the local market in July 2026.

• The Top ASX emerging healthcare stocks July 2026 discussed here span medicinal cannabis, neurological therapeutics, respiratory and emergency medicine, and inflammation and fibrosis drug development.

• Six ASX pharmaceutical stocks — Clinuvel (ASX:CUV), CogState (ASX:CGS), AFT Pharmaceuticals (ASX:AFP), Starpharma (ASX:SPL), Mayne Pharma (ASX:MYX) and Aroa Biosurgery (ASX:ARX) — span specialty pharma, neurological assessment, branded medicines, drug delivery, generics and biosurgery.

• The top ASX biotech stocks July 2026 conversation spans five very different business models, from commercial-stage radiopharmaceuticals to pre-revenue RNA precision medicine.

• Four ASX small-cap biotech stocks — Imugene (ASX:IMU), Genetic Signatures (ASX:GSS), Cynata Therapeutics (ASX:CYP) and Botanix Pharmaceuticals (ASX:BOT) — span oncology immunotherapy, molecular diagnostics, cell therapy and dermatology.

• The top ASX drug development stocks July 2026 discussed here span four distinct therapeutic areas: central nervous system, musculoskeletal, oncology and fibrosis, and radiopharmaceuticals.

• Five Australian healthcare stocks — Artrya (ASX:AYA), Beamtree (ASX:BMT), Doctor Care Anywhere (ASX:DOC), ImExHS (ASX:IME) and Monash IVF (ASX:MVF) — are examined through a shared lens of clinical-workflow innovation and medical service delivery.